Leslie Harrold to Certolizumab Pegol
This is a "connection" page, showing publications Leslie Harrold has written about Certolizumab Pegol.
Connection Strength
0.598
-
Harrold LR, Litman HJ, Saunders KC, Dandreo KJ, Gershenson B, Greenberg JD, Low R, Stark J, Suruki R, Jaganathan S, Kremer JM, Yassine M. One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry. Arthritis Res Ther. 2018 01 02; 20(1):2.
Score: 0.598